Trial · NCT01179113
Esmolol Infusion During Laminectomy: Effect on Quality of Recovery
NCT01179113, Phase 4, Terminated, Cedars-Sinai Medical Center; results first posted 2016-08-30
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Esmolol Infusion During Laminectomy: Effect on Quality of Recovery. Trials, record NCT01179113. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01179113
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Esmolol Infusion During Laminectomy: Effect on Quality of Recovery
- NCT number
- NCT01179113
- Status
- Terminated
- Phases
- Phase 4
- Enrollment
- 33 participants, actual
- Lead sponsor
- Cedars-Sinai Medical Center
- Conditions
- Laminectomy
- Interventions
- Esmolol, Saline
- First posted
- 2010-08-11
- Last updated
- 2016-11-02
- Results first posted
- 2016-08-30
Source ClinicalTrials.gov
Registered outcomes3
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Post-operative Pain Using Verbal Rating Scale (VRS) | 1 day | Verbal Rating Scale goes from 0 to 10, where: 0 indicates= No pain" and 10 indicates= The worst possible pain The information was be recorded by study staff and data obtained from patient and patient charts from post-anesthesia care unit (PACU) stay |
| Secondary | Opioid Consumption in PACU Obtained From the Recorded Data | 1 day | Postoperative use of opioid (Hydromorphone) consumption inside hospital at PACU (recorded by study staff and data obtained from patient charts). |
| Secondary | Postoperative Nausea and Vomiting | 1 day | Number of participants that experienced Postoperative nausea and vomiting using at PACU |
Source ClinicalTrials.gov
Outcomes3
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Post-operative Pain Using Verbal Rating Scale (VRS) | 1 day | Scores on a scale | MEAN | |
| SECONDARY | Opioid Consumption in PACU Obtained From the Recorded Data | 1 day | mg | MEAN | |
| SECONDARY | Postoperative Nausea and Vomiting | 1 day | participants | NUMBER |
Source ClinicalTrials.gov
Results by group6
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Post-operative Pain Using Verbal Rating Scale (VRS) | Placebo | 4 | Standard Deviation 4 | Scores on a scale | |
| Post-operative Pain Using Verbal Rating Scale (VRS) | Esmolol | 5 | Standard Deviation 3 | Scores on a scale | |
| Opioid Consumption in PACU Obtained From the Recorded Data | Placebo | 1.5 | Standard Deviation 0.6 | mg | |
| Opioid Consumption in PACU Obtained From the Recorded Data | Esmolol | 2 | Standard Deviation 2.6 | mg | |
| Postoperative Nausea and Vomiting | Placebo | 2 | participants | ||
| Postoperative Nausea and Vomiting | Esmolol | 0 | participants |
Source ClinicalTrials.gov
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Placebo | 17 | |
| Overall Study | STARTED | Esmolol | 16 | |
| Overall Study | COMPLETED | Placebo | 17 | |
| Overall Study | COMPLETED | Esmolol | 16 | |
| Overall Study | NOT COMPLETED | Placebo | 0 | |
| Overall Study | NOT COMPLETED | Esmolol | 0 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Placebo | ||
| Total, all-cause mortality | Esmolol | ||
| Total, other adverse events | Placebo | 0 | 17 |
| Total, other adverse events | Esmolol | 0 | 16 |
| Total, serious adverse events | Placebo | 0 | 17 |
| Total, serious adverse events | Esmolol | 0 | 16 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons2
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
| Esmolol vs Placebo: Postoperative Nausea and Vomiting | Trial comparisons |
| Esmolol vs Placebo: serious adverse events | Trial comparisons |
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT01179113
GET https://conductscience.org/api/trials/v1/NCT01179113/registered